Increased CX3CL1 in cerebrospinal fluid and ictal serum t-tau elevations in migraine: results from a cross-sectional exploratory case-control study
DiscussionCX3CL1 in CSF is a novel potential fluid biomarker of migraine that is unrelated to the headache status. Serum t-Tau is linked to the headache phase but not interictal migraine. These data need to be confirmed in a larger hypothesis-driven prospective study. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - April 2, 2024 Category: Neurology Source Type: research
The burden attributable to primary headache disorders in children and adolescents in Ethiopia: estimates from a national schools-based study
ConclusionsThe high prevalence of headache among children and adolescents in Ethiopia, who represent half its population, is associated with substantial burden. Lost school time is probably the most important consequence. Estimates suggest a quite deleterious effect, likely to be reflected in both individual prospects and the prosperity of society. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - April 2, 2024 Category: Neurology Source Type: research
Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab
ConclusionsImprovements in HRQoL experienced by patients treated with eptinezumab can be substantially explained by its effect on migraine frequency and PI-MBS. Therefore, in addition to MMD reduction, healthcare providers should discuss PI-MBS improvements, since this may impact HRQoL. Health technology policymakers should consider implications of these findings in economic evaluation, as they point to alternative measurement of quality-adjusted life years to capture fully treatment benefits in cost-utility analyses.Trial registration ClinicalTrials.gov (Identifier:NCT04418765; EudraCT (Identifier: 2019 –004497-25; URL:...
Source: The Journal of Headache and Pain - March 28, 2024 Category: Neurology Source Type: research
Frequency and predictors of headache in the first 12 months after traumatic brain injury: results from CENTER-TBI
ConclusionsHeadache is a common symptom after TBI, especially in female and younger patients. It typically decreases in the first 3 months before stabilising. However, more than a quarter of patients still experienced headache at 12 months after injury. Translational research is needed to advance the clinical decision-making process and improve targeted medical treatment for headache.Trial registrationClinicalTrials.gov NCT02210221. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - March 25, 2024 Category: Neurology Source Type: research
Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial
ConclusionsBased on high persistence and patient satisfaction rates, the 100-mg dose appears optimal for most patients. For those who adjusted dose levels, dose adjustments appeared beneficial to improve efficacy or tolerability, retaining patients on treatment. Collectively, the data suggest that patients who experienced efficacy continued to use lasmiditan regardless of the occurrence or frequency of AEs, and continued use appeared associated with fewer AEs.Trial registrationEuropean Union Drug Regulating Authorities Clinical Trials Database (EudraCT): 2018 –001661-17; ClinicalTrials.gov: NCT03670810; registration date...
Source: The Journal of Headache and Pain - March 25, 2024 Category: Neurology Source Type: research
Headache in the adult population of Cameroon: prevalence estimates and demographic associations from a cross-sectional nationwide population-based study
ConclusionsHeadache disorders are prevalent in Cameroon. As in Zambia and Ethiopia, estimates for both migraine and TTH exceed global mean estimates. Attributable burden is yet to be reported, but these findings must lead to further research, and measures to develop and implement headache services in Cameroon, with appropriate management and preventative strategies. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - March 21, 2024 Category: Neurology Source Type: research
The burden of headache disorders in North India: methodology, and validation of a Hindi version of the HARDSHIP questionnaire, for a community-based survey in Delhi and national capital territory region
ConclusionThis study validates the Hindi version of HARDSHIP, finding its performance similar to those of other versions. It can be used to conduct population surveys in other Hindi-speaking regions of India. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - March 19, 2024 Category: Neurology Source Type: research
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis
ConclusionsErenumab is cost-effective versus topiramate as a preventive treatment for EM and versus placebo for patients with CM from the perspective of the Spanish National Health System. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - March 15, 2024 Category: Neurology Source Type: research
CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society
ConclusionsMost of the respondents recommended CGRPmAbs to patients with ≥ 2 preventive failures, followed by ≥ 1. The MMD threshold ranged mostly from ≥ 4 to ≥ 10. The concern for costs was raised as a major limiting factor for prescribing CGRPmAbs. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - March 15, 2024 Category: Neurology Source Type: research
Specific cognitive and psychological alterations are more strongly linked to increased migraine disability than chronic migraine diagnosis
ConclusionsThe classification of migraine patients based on neuropsychological characteristics demonstrates a more effective separation of groups in terms of disability compared to categorizing them based on the chronic or episodic diagnosis of ICHD-3. These findings could reveal biological changes that might explain differences in treatment responses among apparently similar patients. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - March 15, 2024 Category: Neurology Source Type: research
Societal and economic burden of migraine in Spain: results from the 2020 National Health and Wellness Survey
ConclusionsHaving migraine not only causes a massive impact on patients ’ quality of life and ability to work, but it also generates considerable economic costs for society. In Spain, having migraine was associated to 1.7 higher costs per patient. The clinical and economic burden increases with the frequency of headaches but is higher than controls even in patients su ffering from 1–3 MHD.Graphical Abstract (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - March 15, 2024 Category: Neurology Source Type: research
Calcitonin receptor, calcitonin gene-related peptide and amylin distribution in C1/2 dorsal root ganglia
ConclusionsAmylin and CGRP could both be local peptide agonists for CTR-based receptors in upper cervical DRG, potentially acting through autocrine and/or paracrine signalling mechanisms to modulate neuron function. Amylin and its receptors could represent novel pain targets. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - March 14, 2024 Category: Neurology Source Type: research
Decoding pain through facial expressions: a study of patients with migraine
ConclusionFacial expressions, particularly lid tightener actions, served as inherent indicators of headache intensity in individuals with migraine, even during resting conditions. This indicates that the proposed approach holds promise for providing a subjective evaluation of headaches, offering the benefits of real-time assessment and convenience for patients with migraine. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - March 11, 2024 Category: Neurology Source Type: research
The glymphatic system in migraine and other headaches
AbstractGlymphatic system is an emerging pathway of removing metabolic waste products and toxic solutes from the brain tissue. It is made of a network of perivascular spaces, filled in cerebrospinal and interstitial fluid, encompassing penetrating and pial vessels and communicating with the subarachnoid space. It is separated from vessels by the blood brain barrier and from brain tissue by the endfeet of the astrocytes rich in aquaporin 4, a membrane protein which controls the water flow along the perivascular space. Animal models and magnetic resonance (MR) studies allowed to characterize the glymphatic system function an...
Source: The Journal of Headache and Pain - March 11, 2024 Category: Neurology Source Type: research
Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials
ConclusionsOverall, atogepant is safe and well tolerated in pooled RCTs and LTS trials for the preventive treatment of EM in adults.Trial registrationClinicalTrials.gov identifiers: NCT02848326 (MD-01), NCT03777059 (ADVANCE), NCT03700320 (study 302), NCT03939312 (study 309).Graphical Abstract (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - March 11, 2024 Category: Neurology Source Type: research
